Reneo Raises $95 Million for Rare Mitochondrial Disease
BIOTECH: Funding Coming From Well-Known Industry Investors
By FRED GRIER
TABLE OF CONTENTS
Less than two years after launching its new venture with $50 million in the bank, Reneo Pharmaceuticals follows up in a $95M Series B to further its mission to treat diseases of the mitochondria. The company also tapped Gregory Flesher, as its new CEO....
Read latest San Diego Business Journal online.